$41.10
3.81% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Veracyte Inc Stock price

$41.10
+8.07 24.43% 1M
+20.30 97.60% 6M
+13.59 49.40% YTD
+14.73 55.86% 1Y
-1.11 2.63% 3Y
+12.63 44.36% 5Y
+34.49 521.79% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+1.51 3.81%
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Key metrics

Market capitalization $3.19b
Enterprise Value $2.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 51.89
EV/Sales (TTM) EV/Sales 6.89
P/S ratio (TTM) P/S ratio 7.49
P/B ratio (TTM) P/B ratio 2.71
Revenue growth (TTM) Revenue growth 23.95%
Revenue (TTM) Revenue $425.33m
EBIT (operating result TTM) EBIT $11.26m
Free Cash Flow (TTM) Free Cash Flow $56.48m
Cash position $274.08m
EPS (TTM) EPS $-0.14
P/E forward 114.17
P/S forward 7.18
EV/Sales forward 6.60
Short interest 4.46%
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Veracyte Inc forecast:

10x Buy
83%
1x Hold
8%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Veracyte Inc forecast:

Buy
83%
Hold
8%
Sell
8%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
425 425
24% 24%
100%
- Direct Costs 149 149
10% 10%
35%
276 276
33% 33%
65%
- Selling and Administrative Expenses 174 174
23% 23%
41%
- Research and Development Expense 68 68
38% 38%
16%
35 35
102% 102%
8%
- Depreciation and Amortization 24 24
22% 22%
6%
EBIT (Operating Income) EBIT 11 11
187% 187%
3%
Net Profit -9.27 -9.27
81% 81%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Neutral
Seeking Alpha
19 days ago
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Neutral
Business Wire
20 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation,” said Marc Stapley, Veracyte's chief executive officer. “Looking ahead, we see...
Neutral
Business Wire
27 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthcare Conference – Rancho Palos Verdes, CA Fireside Chat on November 12th at 2:45 p.m. Eastern Time Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA Fireside Chat on November 13th a...
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Employees 815
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today